BX471 Hydrochloride Catalog No.:M8599-10 4 nM (4-h preincubation)

4 nM (4-h preincubation)

9 nM in A549 cell

is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen

HQNO concentrations are varied from 0 to 100 μM and 0 to 300 μM for wild-type (WT) and I379E C

and 94% in the 10 mg/kg

BX471 Hydrochloride Catalog No.:M8599-10 4 nM (4-h preincubation)BX 471, also known as ZK 811752, is a potent, selective non peptide CCR1 antagonist (Ki = 1 nM for human CCR1). BX 471 exhibits 250 fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. BX 471 was developed Berlex and its parent company, Schering AG. BX 471 is the lead in a series of non peptide chemokine receptor 1 (CCR1) antagonists, for the potential treatment of autoimmune diseases, in particular multiple sclerosis (MS). In March 2000, BX 471 was